Show simple item record

dc.contributor.authorDowsett, M
dc.date.accessioned2018-07-11T10:57:04Z
dc.date.issued2004-01
dc.identifier.citationBreast cancer research and treatment, 2004, 87 Suppl 1 pp. S11 - S18
dc.identifier.issn0167-6806
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2031
dc.identifier.eissn1573-7217
dc.identifier.doi10.1007/s10549-004-1578-3
dc.description.abstractcDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with clinical outcomes. In this study, adjuvant tamoxifen and anastrozole ('Arimidex') were compared alone and in combination in more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival, time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision, local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program, these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.
dc.formatPrint
dc.format.extentS11 - S18
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectTamoxifen
dc.subjectNitriles
dc.subjectTriazoles
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectPrognosis
dc.subjectDisease-Free Survival
dc.subjectChemotherapy, Adjuvant
dc.subjectOligonucleotide Array Sequence Analysis
dc.subjectGene Expression Profiling
dc.subjectDrug Resistance, Neoplasm
dc.subjectPatient Care Planning
dc.subjectFemale
dc.subjectBiomarkers, Tumor
dc.subjectAnastrozole
dc.titleBiomarker investigations from the ATAC trial: the role of TA01.
dc.typeJournal Article
rioxxterms.versionofrecord10.1007/s10549-004-1578-3
rioxxterms.licenseref.startdate2004-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBreast cancer research and treatment
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublished
pubs.volume87 Suppl 1
pubs.embargo.termsNot known
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record